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Abstract
In humans, cystic fibrosis (CF) lung disease is characterised by chronic infection, inflammation, airway remodelling,
and mucus obstruction. A lack of pulmonary manifestations in CF mouse models has hindered investigations of
airway disease pathogenesis, as well as the development and testing of potential therapeutics. However, recently
generated CF animal models including rat, ferret and pig models demonstrate a range of well characterised lung
disease phenotypes with varying degrees of severity. This review discusses the airway phenotypes of currently
available CF animal models and presents potential applications of each model in airway-related CF research.
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Background
Animal models of cystic fibrosis (CF) are crucial for un-
derstanding CF pathogenesis and developing therapeutic
strategies. Given that CF affects multiple organs includ-
ing the gastrointestinal tract, lungs, pancreas, liver, and
reproductive organs, it desirable to generate animal
models that accurately capture all disease facets. For the
past 20 years, in vivo CF-related research has predomin-
ately used genetically modified murine models [1]. These
mouse models have proven invaluable for studying as-
pects of CF pathophysiology, however, they have import-
ant limitations. Obvious disparities between murine and
human anatomy and physiology mean that phenotypes
observed in humans are not always reproduced in mice
[2]. Investigating some features of CF airway disease in
mouse models has proven problematic, as CF mice fail
to develop hallmark features including mucus obstruc-
tion, chronic bacterial infections, and persistent inflam-
mation. Of all clinical manifestations associated with
human CF, progressive lung disease is the predominant
cause of morbidity and mortality among patients [3]. As
such, an accurate animal model of CF lung disease initi-
ation and progression is imperative for investigating
pathogenesis, identifying potential treatment targets, and
testing experimental therapies.
Following the generation of CF murine models, it be-
came apparent that species characteristics are important
to consider when developing an animal model of CF
lung disease. Traits that may influence the choice of spe-
cies include airway cellular architecture, particularly the
distribution and abundance of submucosal glands, dom-
inance of alternative chloride secretory pathways, and
conservation of the structure and function of the cystic
fibrosis transmembrane conductance regulator (CFTR)
protein [1]. Since the development of CF mouse models,
advances in genetic engineering have facilitated the gen-
eration of a number of alternative models including a
CFTR knockout rat [4], knockout ferret [5], two knock-
out pig models [6, 7], and a pig harbouring the common
Phe508del CFTR mutation [6]. There are also early re-
ports of CFTR knockout and Phe508del mutant CF
rabbit models being developed [8]. Due to the similar-
ities between the ovine and human lung, generation of a
CF sheep model has long been proposed [9]. Although a
CF sheep model has not yet been established, rapid ad-
vances in gene editing could promote its generation in
the near-future.
This review details the airway disease phenotypes of
existing CF animal models, and examines their strengths
and weaknesses for basic and pre-clinical research.
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CF lung disease pathophysiology
Understanding the underlying pathophysiology of CF lung
disease is necessary prior to examining the phenotypes ob-
served in animal models. Under normal conditions, the
CFTR protein functions as an epithelial anion channel
responsible for cyclic-AMP-dependent chloride and bicar-
bonate secretion, as well as the regulation of epithelial so-
dium channels (ENaC) [10]. CF arises when mutations
occur in the CFTR gene, subsequently disrupting epithe-
lial ion transport. To date, over 2000 disease-causing
CFTR mutations have been identified [11]. These muta-
tions are classified into 6 categories based on the mechan-
ism of CFTR dysfunction including defective protein
synthesis and processing, dysfunctional channel regulation
and conduction, and reduced protein synthesis and stabil-
ity [12]. The most common CF-causing mutation is the
Class II mutation Phe508del, with approximately 90% of
CF patients carrying one copy [11].
Although the role of CFTR in transepithelial ion trans-
port is widely accepted, the exact mechanisms under-
lying CF lung disease development have long been
debated. Several hypotheses have been proposed regard-
ing the pathogenesis of CF lung disease [13]. The leading
theory with a large body of supporting evidence is
known as the “low volume” hypothesis [14–16]. This
theory postulates that reduced transepithelial chloride
transport due to dysfunctional CFTR, as well as in-
creased sodium absorption caused by a lack of CFTR-
dependent inhibition of ENaC, creates an ion imbalance
that leads to osmotically-driven water absorption into
the tissues, and in turn, reduced airway surface layer
(ASL) hydration [3, 10]. The depleted ASL results in de-
hydration of the mucus layer and consequently, viscous
mucus adheres to airway surfaces. Onset of mucus-stasis
and impaired mucociliary clearance (MCC) result in in-
effective removal of inhaled microorganisms [17].
Bacteria adhere to the airway mucus eventually resulting
in the formation of biofilms that effectively evade anti-
microbial substances and host neutrophils. Over time,
more resistant and atypical organisms colonise the air-
ways including mycobacteria, yeast, and fungus. A state
of chronic lung infection incites persistent inflammatory
responses that lead to destruction of the airway tissue,
bronchiectasis, progressive loss of lung function, and ul-
timately respiratory failure [18].
Murine models
Shortly after the discovery of the CFTR gene in 1989 the
first CF mouse model was generated [19]. Since then, at
least 15 CF mouse models have been developed and
characterised (reviewed in detail elsewhere [20–22]).
Two major groups of CF mouse models exist: null alleles
(knockouts) with no detectable mRNA or functional
CFTR protein, and mutant alleles with common human
CF-causing mutations (e.g. Phe508del or Gly551Asp) in-
troduced into the mouse CFTR sequence [23]. The lim-
ited utility of CFTR knockout strains due to early-fatal
intestinal obstruction led to the development of a third
category; “gut corrected” transgenic CF mice. In this
model, human CFTR cDNA is expressed under the con-
trol of the rat fatty acid binding protein (FABP)
promoter, thereby localising expression to the intestinal
epithelium [24], and subsequently increasing the longev-
ity of CF mice [25]. Humanised mouse models that
exclusively express human CFTR with common
CF-causing mutations are also currently under develop-
ment [26].
Lung disease phenotype in CF mice
Disease phenotypes and severity among CF mouse models
tend to be heterogeneous due to the diversity of genetic
backgrounds and variation in gene targeting strategies
used to generate the animals [25]. Although early charac-
terisation studies initially reported that CF mice did not
demonstrate any lung pathology [19], emerging evidence
suggests that they do in fact exhibit some phenotypes
reminiscent of human CF lung disease. Similar to the early
pulmonary phenotype observed in human CF airways,
multiple studies have demonstrated that CF mice display
altered respiratory mechanics [27–30]. Furthermore, when
a state of hyperinflammation is induced in the lungs of CF
and wild-type mice using repeated exposure of an inflam-
matory stimuli (in this case lipopolysaccharide from
Pseudomonas aeruginosa), CF mouse lungs undergo re-
modelling and morphological changes, while the airways
of wild-type mice are able to efficiently recover [31].
Recent studies also indicate that CF mice spontaneously
acquire Bordetella respiratory tract infections [32].
Although CF mice demonstrate features of lung dis-
ease, their use is somewhat limited as they do not ex-
hibit the severe pathology characteristic of established
human CF lung disease consisting of chronic respiratory
infection, inflammation, mucus plugging, and progres-
sive bronchiectasis [23]. Several theories may explain
why CF mice fail to develop the overt lung disease that
is observed in humans. One is that modifier genes are
upregulated in CF mice, leading to partial correction of
the underlying ion transport defects. Dominance of the
calcium-activated chloride channel (CACC) secretory
pathway has been observed in the airway epithelia of CF
mice [33]. It has been suggested that this adaptive mech-
anism compensates for defective CFTR-mediated chlor-
ide transport, thereby rectifying the underlying ion
imbalance, and protecting the murine airways from
disease [33, 34]. In addition to upregulation of the
CACC in CF murine airways, the cAMP-mediated CFTR
pathway normally has a less dominant role in the re-
spiratory epithelium of mice [25].
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The lower airways of adult CF mice do not demon-
strate electrical defects that are characteristic of human
CF airways, including reduced cAMP-mediated chloride
secretion and sodium hyperabsorption. Hyperactivity of
ENaC is important in the pathogenesis of CF lung dis-
ease as it is thought to contribute to the depletion of the
ASL and subsequent cascade of events including mucus
accumulation, impaired MCC, infection and inflamma-
tion, and lung tissue damage [35]. As such, a lack of so-
dium hyperabsorption in the lower airways of CF
murine models may explain the absence of lung disease
development [25]. It is also possible that the structure
and function of CFTR evolved differently in mice. Inves-
tigations into CFTR homology among species reveal that
mouse CFTR is only 88% conserved with human CFTR
at the amino acid level, as such, the murine CFTR chan-
nel exhibits some different pharmacological and gating
properties to human CFTR [36, 37].
CFTR protein in human airways is predominately
expressed in the ciliated epithelium and the submucosal
glands, therefore histological disparities between murine
and human airways may explain the absence of lung dis-
ease in CF mice [38, 39]. Mouse and human airways dif-
fer in cellular architecture; human distal airways are
comprised primarily of ciliated cells, whereas murine
lower airways are largely non-ciliated, secretory, club
cells [25]. Furthermore, human airways have numerous
submucosal glands throughout the trachea and bronchi,
while murine airways only have a small proportion of
these glands in the larynx and proximal trachea [40]. As
submucosal glands are implicated in human CF airway
disease, their scarcity in the murine distal airways could
contribute to the lack of lung pathophysiology [41].
Environmental factors and host-pathogen interactions
may also play a role [20]. It has been hypothesised that
CF lung disease is not effectively modelled without the
presence of pathogens, therefore the conventional hous-
ing of CF mice in semi-sterile, and often specific patho-
gen free (SPF) conditions may prevent development of
the lung disease that is typically observed in humans
with CF [22]. However, this theory does not appear to be
substantiated, as CF mice reared in a non-sterile envir-
onment still fail to develop lung disease [25].
Upper airway and tracheal phenotype in CF mice
Some CF mouse strains display a mild phenotype in the
upper airways and trachea. Characteristics observed in-
clude distended submucosal glands in the nasal mucosa
[42], atrophy of serous gland tissue in the sinuses [19],
hyperplasia of goblet cells in the nasal septa, and a re-
duced ASL in the nasal epithelium [15]. CFTR−/− mouse
models also show notable tracheal abnormalities such as
incomplete cartilage rings [43], and reduced smooth
muscle area [44]. Impaired MCC in the trachea of
CFTRtm1HGU and CFTRtm1UNC strains has also been re-
ported [45], however, these findings have been contested
by others that found MCC was unaffected in
CFTRtm1UNC mice [46].
The nasal epithelium of CF mice demonstrates similar
bioelectric abnormalities to human CF airways including
reduced chloride transport and sodium hyperabsorption.
These defects have been well documented using the
nasal potential difference (NPD) measurement tech-
nique; an assessment that involves placing fluid-filled
cannula electrodes (connected to a millivoltmeter) on
the nasal lining to measure the electrical potential pro-
duced by ion transport across the epithelium in response
to different salt solutions [47]. All CF mice appear to ex-
hibit reduced cAMP-mediated chloride secretion in the
nasal epithelium, which is characteristic of human CF
airways [22, 25]. The hyperactivity of ENaC, a feature
present in human CF nasal epithelium [48], is also ob-
served in the nasal epithelium of most CF mouse models
including knockout [49], CFTRΔF508 [49, 50] and
CFTRG551D strains [51]. When amiloride (a drug that
blocks ENaC-mediated sodium absorption) is perfused
through the nasal epithelium of a CF mouse, a signifi-
cant depolarisation response occurs, which is consistent
with the presence of sodium hyperabsorption [21].
As the nasal epithelium of CF mice accurately recapit-
ulates the electrophysiological profile of human CF air-
ways, it has proven valuable for testing therapeutic
agents that replace dysfunctional CFTR (i.e. gene therap-
ies) [52], and those that restore normal ion transport
[53, 54]. Mouse strains bearing the Phe508del and
Gly551Asp mutations could be particularly useful for
testing compounds that correct CFTR processing and
trafficking (CFTR correctors), and defective channel gat-
ing (CFTR potentiators). However, some CFTR potentia-
tors that strongly augment human CFTR do not have
any effect on murine CFTR, most likely due to differ-
ences in the murine CFTR channel properties [20]. Once
developed, hCFTR CF mouse models will be valuable for
trialling small molecule drugs. Although the nasal epi-
thelium of CF mice has provided a useful platform for
trialling therapeutics [52–54], it should be noted that
murine nasal mucosa is composed of 40% olfactory epi-
thelium and 60% respiratory epithelium (depending on
location), thus differing substantially from the cellular
composition of human lungs, the intended target organ
of these therapies [12].
Bacterial challenge rodent models
The absence of overt lung disease in CF mouse models,
even under non-sterile conditions, led some investiga-
tors to trial more radical bacterial-challenge approaches
to simulate a chronically infected and inflamed airway
[20]. In these studies, a range of knockout and mutant
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CF strains were inoculated with P. aeruginosa, an import-
ant pathogen in the development and progression of hu-
man CF lung disease [55]. Bacterial challenge with P.
aeruginosa has previously yielded variable results, most
likely due to differences in dose, delivery method, dosing
frequency, and the clinical isolate used. Despite this, many
of the challenged CF mouse strains demonstrated suscep-
tibility to acute P. aeruginosa, characterised by increased
mortality and reduced ability to clear the bacteria when
compared to non-CF control animals [55–58].
In one example, P. aeruginosa laden agarose beads
were intratracheally instilled into CFTRtm1UNC mice.
In addition to increased mortality (when compared to
non-CF controls), challenged mice also demonstrated
a significant pulmonary inflammatory response follow-
ing inoculation, indicated by elevated levels of inflam-
matory markers in bronchoalveolar lavage (BAL) [55].
Studies have also attempted to deliver P. aeruginosa
to CF mice in drinking water, resulting in low levels
of chronic colonisation within CF airways, while wild-
type animals effectively cleared the bacteria [59].
Other CF-related bacterial strains have also been
used, in one study CFTRtm1UNC mice were intrana-
sally challenged with the bacterium Burkholderia
cepacia (B. cepacia). Following instillation, bacteria
persisted in the airways of CF mice and caused severe
bronchopneumonia while wild-type mice remained
healthy [60].
These bacterial challenge studies indicate that the ab-
sence of CFTR in mouse airways is enough to produce
heightened susceptibility to CF-related pathogens [58].
Accordingly, challenged CF mice elicit a sustained in-
flammatory response that could allow for investigations
into the relationship between inflammation and infec-
tion in a CFTR-deficient lung [57], as well as trialling of
novel anti-inflammatory and antibiotic therapies [60,
61]. However, these bacterial challenge mouse models
are limited, as they do not reflect the conditions in
which CF patients acquire and respond to infection.
Furthermore, instilling CF mice with human pathogens
is a somewhat naïve approach as host-pathogen interac-
tions are complex, differ in mice and humans, and do
not solely depend on CFTR activity [20].
In addition to bacterial challenge being performed in
CF mice, models of respiratory infection have also been
established in normal rodents by using key CF-related
bacterial species. Mouse models of chronic Burkhol-
deria cenocepacia [62] and P. aeruginosa [63] infection
have recently proven useful for investigating host-
pathogen interactions of bacterial species that are per-
tinent to CF lung disease. Similarly, a rat model of
chronic P. aeruginosa infection that exhibits pathologic
features of human P. aeruginosa pulmonary infection
has also been developed [64].
Congenic CFTR knockout mouse model
It has been hypothesised that generation of CF mouse
models on mixed genetic backgrounds results in upregu-
lation of modifier genes that prevent the development of
lung disease. To test this theory, the CFTRtm1UNC CF
mouse strain was redeveloped on a single genetic back-
ground and was termed B6-CFTRtm1UNC. Interestingly,
B6-CFTRtm1UNC mice develop lung disease manifesta-
tions including bronchiolar mucus retention, tissue fi-
brosis, hyperinflated alveoli, and alveolar wall thickening
[65]. B6-CFTRtm1UNC mouse lungs also show inflamma-
tory cell recruitment with an influx of neutrophils ob-
served. This inflammatory disease phenotype appears
spontaneous, as analysed mice were housed in SPF con-
ditions with no airway pathogens detected prior to, or
during the onset of inflammation [66].
In the nose, PD measures indicate that the congenic
CF mouse demonstrates reduced chloride secretion,
which is consistent with an absence of CFTR. Unlike
mixed-background CF mouse strains however, the re-
sponse to amiloride does not appear to differ between
congenic CF mice and wild-type, suggesting that con-
genic CF mice do not exhibit sodium hyperabsorption in
the nasal epithelium [65]. Furthermore, B6-CFTRtm1UNC
mice challenged with P. aeruginosa demonstrate reduced
capacity to control infection [67]. It has been speculated
that congenic B6-CFTRtm1UNC mice develop aspects of
lung disease as they lack, or fail to activate alternate
chloride conductance pathways normally present in
mixed background CF mouse models [65].
The B6-CFTRtm1UNC mouse is one of the few models
that exhibits inflammatory lung disease, as such it has
proven useful for exploring the long-debated question of
whether inflammation in CF airways is spontaneous, or in-
duced by infection [66]. Even though the B6-CFTRtm1UNC
mouse demonstrates aspects of CF lung disease, the ori-
ginal mixed-background CF mouse strains continued to
be used. Unexpectedly, generation of another congenic
mouse model based on the CFTRtm1HGU strain resulted in
amelioration of the CF phenotype, rather than an increase
in severity [68]. Given the potential undesired effects of
developing models on mixed-backgrounds, along with the
rapid uptake of new gene editing technologies such as
CRISPR/Cas9, newly generated CF mouse models are
likely to be congenic.
β-ENaC mouse model
Difficulties recapitulating the pathophysiology of CF
lung disease in existing mouse models led to the devel-
opment of the β-ENaC mouse (also known as the
Scnn1b mouse). The β-ENaC mouse is a transgenic
mouse model that overexpresses the β-subunit of ENaC
in the lungs, thereby mimicking the sodium ion trans-
port abnormalities observed in CF human airways [69,
McCarron et al. Respiratory Research  (2018) 19:54 Page 4 of 12
70]. The airways of β-ENaC mice recapitulate the key
processes of CF lung disease initiation, whereby in-
creased airway sodium absorption results in depletion of
the ASL and deficient mucus clearance. Accordingly,
β-ENaC mice exhibit CF-like lung disease with features
including mucus hypersecretion, mucus obstruction in
the conducting airways, MCC impairment (as measured
directly by microdialysis), goblet cell metaplasia, and
neutrophilic airway inflammation [69–71].
Initial studies performed using adult β-ENaC mice
failed to detect spontaneous bacterial infection in the
airways, however, when intratracheally challenged with
Haemophilus influenzae and P. aeruginosa, adult
β-ENaC mice exhibit impaired pathogen clearance when
compared to wild-type mice [69]. More recent studies
involving longitudinal analysis of BAL indicate the pres-
ence of spontaneous lung infection in neonatal β-ENaC
mice, while wild-type neonates had no culturable
bacteria. The same study also revealed that the lung bac-
terial burden and proportion of infected β-ENaC mice
appears to decrease with age, attributable to maturation
of the immune system that occurs during the postnatal
period [72].
The β-ENaC mouse provides a relevant model for in-
vestigating CF lung disease pathogenesis, particularly the
interactions between ion transport, the ASL, and MCC.
The lung disease modelled by the β-ENaC mouse has
already proven useful for developing novel respiratory
diagnostic tools to localise and measure heterogeneity of
lung disease [73]. Furthermore, β-ENaC mice could be
used to evaluate a range of treatments including those
that target ASL depletion, mucus obstruction, and in-
flammation [70]. For instance, the β-ENaC mouse could
be used to trial ENaC inhibition strategies that may re-
store normal sodium transport. Such approaches include
use of ENaC antagonists, silencing ENaC expression
using short-interfering RNAs (siRNAs), and inhibiting
proteases that activate ENaC [35]. However, as CFTR ex-
pression and function are not altered in the β-ENaC
model, it is not suitable for testing therapeutics that re-
place, correct or potentiate CFTR [70].
CF rat model
Limited usability of CF mouse models attracted re-
searchers to other species to use as platforms for devel-
oping a more accurate CF model. Compared to larger
animals, rats have the advantages of a short gestation
(21–23 days) and early sexual maturity (8 weeks),
thereby allowing for rapid breeding. Rats also have fewer
animal husbandry expenses compared to large animals,
and have been used widely for research purposes mean-
ing they are well characterised in terms of physiology,
pharmacology, and toxicology [74]. Moreover, there is a
vast array of rat-specific molecular tools available that
would be difficult to source or develop for other species.
Unlike mice, rats have extensive submucosal glands
present throughout the cartilaginous airways (trachea
and primary bronchi), similar to humans [75]. As
submucosal glands are implicated in the development of
CF lung disease in humans [76], rat lungs are an attract-
ive model.
Airway disease in the CFTR knockout rat model
CFTR−/− rats recapitulate important features of lung dis-
ease that are observed in humans with CF. Histologi-
cally, the respiratory epithelium of the nasal septum in
CF rats is normally developed, however, cells tend to ex-
hibit dilation due to increased levels of intracellular
mucus, indicative of defective mucus secretion. Morpho-
logically, the trachea of ≤ 6-week-old CF rats appears to
develop abnormally, with evidence of diminished tra-
cheal cartilage and gland area when compared to wild
-type rats. CF rats also display significant depletion of
the ASL with a notable reduction in periciliary liquid
(PCL) depth [4]. Furthermore, preliminary findings indi-
cate that young CF rats demonstrate a hyperacidic air-
way surface pH [77], similar to that observed in CF pigs
[78]. Interestingly, a recent study has revealed that ASL
pH is not reduced in children with CF [79].
Despite depletion of the ASL, mucociliary trans-
port (MCT) appears to be unaffected in young CF
rats (< 3 months) [4]. However, early evidence suggests
that as the animal ages and the airway submucosal glands
develop, MCT rates reduce significantly when compared
to wild-type. Preliminary investigations also suggest that
by 6 months of age, CF rats exhibit mucus plugging of
submucosal glands in the large airways [77, 80]. Spontan-
eous infection and inflammation is not present in CF rat
airways, with no differences observed in BAL profiles be-
tween wild-type and CFTR−/− genotypes [4]. Although
spontaneous infection is absent, emerging evidence indi-
cates that similar to CF mice, CF rats have a diminished
ability to clear induced P. aeruginosa infection [81].
CF-like electrophysiological defects are present in the
both the nasal and tracheal epithelium of CF rats as
measured by NPD and short circuit current (Isc), re-
spectively. In the nasal epithelium, CF rats demonstrate
reduced chloride transport and show no evidence of
cAMP-mediated chloride secretion following attempts to
stimulate CFTR with forskolin (a cAMP agonist), both
features consistent with an absence of CFTR. Isc mea-
sures of transepithelial ion transport performed on
freshly excised CF rat tracheal tissue using Ussing cham-
bers demonstrates a markedly lower baseline Isc in CF
rats when compared to wild-type, typical of a CF bio-
electric profile. Furthermore, administration of an in-
hibitor of CFTR-dependent chloride transport to the
tracheal tissue has minimal effect on Isc, suggesting low
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basal CFTR activity [4]. CFTR−/− and wild-type rats
demonstrate similar responses to amiloride in both the
nasal and tracheal epithelium, suggesting that unlike hu-
man CF airways and the nose of CF mice, CF rat airways
do not demonstrate sodium hyperabsorption.
Recapitulation of key CF airway features in the CFTR
−/− rat model including reduced ASL and MCT will pro-
vide opportunities to further investigate the mechanisms
involved in lung disease development. Electrophysio-
logical, MCT and ASL measures may also be useful in
assessing the efficacy of airway-targeted treatments in-
cluding genetic therapies. Despite these and many other
potential applications, the advantages of CF rats such as
their small size, rapid breeding, ease of husbandry, and
display of key airway disease phenotypes, are yet to be
exploited [4]. Additional in-depth investigations of the
airway phenotype are required to reinforce initial charac-
terisation reports, and longitudinal studies are necessary
to follow lung disease development over the lifetime of
the animals. Furthermore, carrying out bacterial chal-
lenge studies in CF rat airways like those performed in
CF mice [57], may reveal disease characteristics that are
otherwise undetected in a non-infected lung. Recent ad-
vances in gene editing will also enable the future devel-
opment of CF rat strains carrying human-specific CFTR
mutations.
CF ferret model
Due to similarities between ferret and human lung cell
biology and anatomy, normal ferret lungs have been
used to model human pulmonary infections including
severe acute respiratory syndrome [82], and influenza
virus [83]. Ferret airways also have important features
that make them attractive for developing a model of CF
lung disease. Like humans, ferret airways have submuco-
sal glands throughout the trachea and primary bronchi
that express high levels of CFTR [38, 84]. Additionally,
the predominant secretory cell type in ferret and human
proximal cartilaginous airways is the goblet cell, unlike
in mice, where the equivalent is the club cell [85]. Ferret
CFTR also has a high degree of amino acid sequence
conservation with human CFTR (95%), and accordingly,
the bioelectric and pharmacologic properties of CFTR
are similar in ferrets and humans [36].
Airway disease in the CFTR knockout ferret model
The CF ferret demonstrates a severe lung phenotype that
is heterogeneous between individual animals. Mucus
plugging is observed in the small and large airways, and
in some cases, causes complete blockage. In addition to
the presence of mucus, pockets of trapped air and de-
flated alveoli (atelectasis) are also present. Dilation of
the submucosal glands and ducts, goblet cell hyperplasia,
and presence of inflammatory cells and bacterial
colonies within the mucus are all observed in CF ferret
airways. In instances where bronchopneumonia is
present, purulent inflammation, necrosis, and pulmonary
consolidation can also occur. CF ferrets also occasionally
present with mucus accumulation and inflammation in
the sinuses. When MCC is measured using fluorescent
bead migration in ex vivo tracheas, CF ferrets exhibit a
significantly reduced (by seven-fold) MCC rate in com-
parison to their non-CF counterparts [86].
Bioelectric Isc measures performed on CF ferret tra-
cheal tissue demonstrate electrophysiological abnormal-
ities that are typical of CF [5]. CF ferret tracheal
epithelia exhibits a large reduction in transepithelial
current when an inhibitor of non-CFTR epithelial chlor-
ide channels is delivered, suggesting decreased CFTR ac-
tivity. Furthermore, delivery of various cAMP agonists
(e.g. forskolin) to the tracheal tissue does not appear to
stimulate significant responses, and subsequent addition
of a CFTR inhibitor also results in little change in ion
transport, features that are all consistent with a lack of
CFTR function and subsequent defective cAMP-
dependent chloride transport [87]. Fluid secretion from
the submucosal glands is also substantially reduced in
CF ferret tracheal tissue, a feature that is also present in
human CF proximal airways [5]. Interestingly, there is
no difference in ENaC activity in tracheal tissue taken
from CF and wild-type animals > 3 months of age (as
measured by Ussing chamber Isc analysis). However,
there is some evidence that CF ferrets display an age-
dependent increase in ENaC activity that is not observed
in wild-type controls, suggesting a possible link between
ENaC activity and airway disease progression [86].
In striking contrast to CF rodent models, CF ferrets
are highly susceptible to lung infection, and antibiotic
treatment is required from birth to ensure survival.
Bacteriologic studies have identified a diverse range of
bacteria in the lungs of CF ferrets with the most com-
mon species from the genera Streptococcus, Staphylococ-
cus, and Enterococcus. Interestingly, enteric bacterial
species from the Enterococcus and Escherichia genera
are abundant in the lungs of CF ferrets. The significant
overlap in lung and intestinal flora suggests that the
intestines provide a primary source of lung-colonising
bacteria [5].
The CF ferret is one of the few models that exhibits
spontaneous lung infection, a crucial factor implicated in
CF lung disease. However, the onset of lung infection in
the CF ferret is rapid and severe, differing from the slow
progressing chronic infection observed in humans [88].
As CF ferrets are susceptible to lung infections continu-
ous antibiotic treatment and ongoing high levels of care
are required from birth to improve survival [5]. Along
with infection, the ferret lungs demonstrate mucus plug-
ging, inflammation, and reduced MCC, all important
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manifestations of a CF airway. Given this, the ferret
could be useful for testing the efficacy of potential thera-
peutics under conditions of infection and inflammation,
which has not been possible with previous CF models.
The presence of spontaneous lung infection will also as-
sist in understanding the complex changes in the CF
lung microbiome with disease progression [86]. One dis-
advantage of the CF ferret model is the lack of ENaC
dysregulation in the airway tissues, a process thought to
be significant in the pathogenesis of lung disease [36].
Along with lung disease, CF ferrets also develop a
range of gastrointestinal pathologies, similar to those ob-
served in CF patients. Notably, CF ferrets demonstrate a
high prevalence of meconium ileus at birth (75% of kits)
that is often fatal, as well as pancreatic dysfunction, mal-
nutrition, and liver disease [5, 89]. To alleviate this se-
vere gastrointestinal phenotype, a CFTR−/− model
expressing ferret CFTR cDNA under direction of the
FABP promoter has been developed. This gut-corrected
model will enable more CF ferrets to survive to maturity
thereby allowing lung disease progression to be investi-
gated longitudinally [5].
CF pig models
Parallels between humans and pigs in regards to anat-
omy, physiology, biochemistry, size, life span, and genet-
ics make pigs a suitable candidate for modelling a range
of human diseases. Porcine lungs share several anatom-
ical and histological features with human lungs, includ-
ing similar tracheobronchial tree structure, and
abundance of airway submucosal glands [90]. Pigs have
previously been used to model pulmonary diseases in-
volving inflammation and infection such as chronic
bronchitis [91]. Furthermore, as human CF lung disease
progresses over the lifetime of an individual, the longev-
ity of pigs allows for long-term investigations of lung
disease pathogenesis and assessment of therapeutics,
which is not possible in rodent or ferret models due to
their relatively short lifespan or disease severity, respect-
ively [90]. The pig CFTR amino acid sequence is also
95% conserved with human, and the electrophysiological
properties of porcine airway epithelium and submucosal
glands resemble those observed in humans [36, 92].
Adeno-associated virus-mediated gene targeting of
CFTR was used to generate the first CF pig models con-
taining either a null allele (CFTR−/−) or the common
Phe508del mutation (CFTRΔF508/ΔF508) [6, 93]. Cross-
breeding of CFTR+/− and CFTR+/ΔF508 heterozygotes
was also performed to produce a third model, denoted
CFTR-/ΔF508 [94]. Shortly thereafter, Klymiuk et al. gen-
erated another knockout CF pig using an alternative ap-
proach that involved sequential targeting of CFTR using
bacterial artificial chromosome (BAC) vectors [7].
Following breeding of the first CF pigs, it was realised
that maintenance of the animals requires intensive and
costly husbandry due to the severe gastrointestinal
phenotype. Newborn CF pigs have a 100% penetrance of
meconium ileus, with piglets requiring surgery soon
after birth to relieve the obstruction. CF pigs also dem-
onstrate pancreatic insufficiency and other gut-related
issues requiring treatments including enzyme replace-
ment therapy to aid digestion, oral vitamin supplements
to prevent malnutrition, oral proton pump inhibitors or
H2 blockers to control gastric acid, and laxatives to pre-
vent bowel obstruction [93]. Using the same approach
employed to create the gut-corrected CF mouse and
ferret models, a transgenic CFTR−/− pig was generated
to express porcine CFTR in the intestines thereby
overcoming the need for surgical correction of meco-
nium ileus at birth [95].
Airway disease in CF pig models
CFTR−/−, CFTRΔF508/ΔF508 and CFTR-/ΔF508 pig strains
(hereafter collectively referred to as CF pigs) spontan-
eously develop key features of human CF lung disease
within months of birth. These manifestations include
airway inflammation, infection, tissue remodelling,
mucus accumulation, and obstruction [94]. As in human
CF populations, the severity of the lung phenotype varies
between animals, with individual lobes also demonstrat-
ing heterogeneity [93]. Examination of neonatal CF pig
airways shows no evidence of inflammation, comparable
to newborn humans with CF [94, 96]. BAL profiles also
indicate no difference in leukocyte and interleukin 8
(IL-8) concentrations between newborn CF and non-CF
pigs. Over time however, inflammation ensues, ranging
from mild to severe leukocytic infiltration, with severe
cases occasionally exhibiting ulceration and abscess for-
mation of the airway wall, and destruction of submuco-
sal glands. Shortly after birth, CF pig lungs demonstrate
defective bacteria eradication with newborn CF pigs
challenged with Staphylococcus aureus failing to eradi-
cate the bacteria as effectively as wild-type pigs [94].
This defective bacterial killing has been attributed to re-
duced airway surface pH in the CF pig and subsequent
diminishing of the ASL antimicrobial function [78].
CF pigs demonstrate heterogeneous airway remodel-
ling, with some cases showing evidence of goblet cell
hyperplasia, airway wall thickening, and rarely, distended
submucosal glands [94]. As observed clinically in infants
with CF [97, 98], CF pigs present with airway obstruc-
tion comprising of atelectasis, hyperinflation, air trap-
ping, and pneumonia [99]. Purulent material appears to
obstruct the trachea and bronchi, often containing
bacteria, neutrophils, and macrophages [94]. Tracheal
abnormalities are also observed in CF pigs including a
triangular rather than circular shaped trachea [7],
smaller lumen area and circumference, irregular cartilage
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rings, and altered smooth muscle [93, 100]. Similar tra-
cheal malformations have been noted in CF mouse
models [43], CF rats [4], and infants with CF [100].
Interestingly, newborn CF pigs do not demonstrate re-
duced PCL depth in the trachea [101], but they do ex-
hibit impaired MCT [102].
A range of ion transport measures performed on the
nasal, tracheal and bronchial epithelia of CF pigs using tis-
sues, cultures and in vivo approaches reveals electro-
physiological defects consistent with loss of CFTR activity
[101]. These abnormalities tend to be more pronounced
in CFTR−/− airway epithelia when compared to
CFTRΔF508/ΔF508 pigs, most likely due to the CFTRΔF508/
ΔF508 epithelia retaining some residual CFTR function
[93]. Characteristic of CF, CFTR-mediated chloride trans-
port is substantially reduced in the nasal, tracheal, and
bronchial epithelium of CF pigs when compared to wild-
type. CF pig nasal epithelia also exhibits a CF-like re-
sponse to amiloride perfusion, but the trachea does not.
Further investigation into this phenomenon revealed that
the amiloride response observed in the CF pig nasal epi-
thelia was due to reduced CFTR-mediated chloride con-
ductance rather than sodium hyperabsorption [101].
Excised tracheal tissue from CF pigs also demonstrates di-
minished bicarbonate conductance, which is consistent
with the human CF phenotype [93, 101].
Given that CF pigs capture many features of human
CF airway disease, they have been useful for several re-
search applications including investigations of lung dis-
ease pathogenesis [94], studying electrolyte transport
defects [101], and exploring mechanisms involved in
CFTR-Phe508del biosynthesis and misprocessing [92].
CF pigs have also provided a useful platform for explor-
ing the origins of inflammation and infection within CF
airways [94], identifying the role of ASL acidification in
lung disease development [78], and trialling viral-
mediated airway gene therapy approaches [103, 104]. In
the future, CF pigs may also be useful for the long-term
testing of therapeutics such as CFTR modulators, and
for assessing airway disease prevention strategies [105].
Concluding remarks
CF mouse models have proven useful for researching
many facets of CF, but their use for airway-related inves-
tigations is restricted because they only exhibit mild fea-
tures of CF lung disease, and induced airway disease
using bacterial challenge approaches has limitations. Al-
though the nasal epithelium of CF mice has provided a
platform for exploring pathogenesis and assessing thera-
peutics, the lack of overt lower airway disease manifesta-
tions and the high degree of phenotype heterogeneity
between strains means that new models are required.
The β-ENaC mouse has provided a useful alternative to
CF mice as it models lower airway obstruction, although
it is not suitable for all applications (e.g. trialling CFTR-
directed therapies) as CFTR expression and function are
unaffected. Endeavours to overcome deficiencies of the
available mouse models has led to development of new
CF animal models including CF rat, ferret, and pig
models. These models demonstrate an array of CF lung
disease phenotypes with varying severity, as outlined in
Table 1.
Rats have intrinsic advantages for routine use as a model
of CF including low cost and maintenance, rapid
reproduction rate, and large litter sizes. The CFTR knock-
out rat demonstrates many pulmonary phenotypes includ-
ing airway surface defects, a CF-like electrical profile in
nasal and tracheal tissues, abnormal mucus production,
and tracheal malformations. Although promising, further
in-depth characterisation of the airway disease that is
present, or readily inducible, would aid investigators in
using this model for research applications.
The lung disease modelled by the CF ferret shares sev-
eral similarities to that observed in humans. The concur-
rent presence of airway inflammation, infection, and
mucus obstruction provides a highly valuable platform
for further elucidating lung disease pathogenesis, as well
as trialling therapies in a lung environment that closely
replicates that of a human CF patient. However, the se-
vere disease phenotype of the CF ferret model continues
to limit its use, as the ferrets often have poor survival
and require ongoing antibiotic treatment, therefore add-
itional husbandry needs may constrain investigations.
Pigs share several airway characteristics with humans
that make them suitable for developing a model of CF
lung disease. Recently generated CFTR knockout and
Phe508del mutant pig models exhibit lung disease hall-
marks including inflammation, airway obstruction, and
infection, traits that will facilitate both basic and pre-
clinical airway-related research. However, CF pig models
have drawbacks that may hinder their usability including
the need for costly therapies to prolong survival of pig-
lets, and the inherent costs and logistical limitations that
arise when using large animal species for research.
Recently, CRISPR/Cas9 has been used to generate
CFTR knockout and Phe508del mutant CF rabbit
models [8]. Rabbits are considered to be an ideal species
for modelling CF lung disease, as their airways are simi-
lar to humans in terms of anatomy and inflammatory re-
sponses [106]. Initial characterisation reports of the CF
rabbit models reveal a CF-like lung phenotype including
evidence of sodium hyperabsorption in trachea, mucus
plugging, and bacterial infection in the lower airways,
with BAL predominately containing bacteria from the
Streptococcus and Staphylococcus genera [8]. Although
these findings are preliminary, the CF rabbit models
show promise for future use in CF-related research.
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Animal models will continue to play a fundamental
role in furthering our understanding of CF. Along with
the development of rapid and precise gene editing tech-
nologies such as CRISPR/Cas9 comes the potential for
new species to be used as platforms for modelling CF, as
well as modification of existing models by introduction
of human-specific CFTR mutations. Animal models that
accurately recapitulate the hallmark features of human
CF lung disease will be crucial in providing researchers
with a resource for trialling experimental lung therapies,
identifying new treatment targets, and elucidating the
complex mechanisms that underlie CF lung disease.
Although a perfect model of CF lung disease does not
exist, each animal model has unique advantages and can
be used in complementary manner to investigate CF-re-
lated questions.
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